Statins in the management of patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis

Neurocritical Care

Volumn 12, Issue 2, 2010, Pages 285-296

  Kramer, Andreas H ^a   Fletcher, Jeffrey J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Meta analysis; Statins; Subarachnoid hemorrhage; Vasospasm Delayed ischemic neurological deficits

Indexed keywords

PRAVASTATIN; SIMVASTATIN;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELAYED ISCHEMIC NEUROLOGICAL DEFICIT; HUMAN; META ANALYSIS; MORTALITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; VASOSPASM;

ANTICHOLESTEREMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SUBARACHNOID HEMORRHAGE;

EID: 77953613257     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-009-9306-9     Document Type: Review

References (35)

1. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neu- rosurg. 1990;73:18-36.
2. Bederson JB, Connolly ES, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke. 2009;40: 994-1025.
3. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. for aneurysmal subarachnoid hemorrhage. Cochrane Database Syst Rev 2007;3: CD000277.
4. van den Bergh WM, Mees SM, Rinkel GJ. Intravenous magnesium versus nimoidpine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery. 2006;59:1152.
5. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1). Randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39:3015-3021
6. Sugawara T, Ayer R, Zhang JH. Role of statins in cerebral vasospasm. Acta Neurochir Suppl. 2008;104:287-290
7. Tseng M, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. 2005;36:1627-1632
8. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke. 2005;36:2024-2026
9. Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke. 2008;39:2622-2626
10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-94.
11. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012
12. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial. 1996;17: 1-12.
13. Shulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273: 408-412
14. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Health Technol Assess. 2003;7:1-173.
15. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453-1457
16. Hijdra A, van Gijn J, Nagelkerke NJ, Vermeulen M, van Crevel H. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19: 1250-1256
17. Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:2315-2321 (Pubitemid 47457575)
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med. 2002;21:1539-1558
19. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315:1533-1537
20. Chou SH, Smith EE, Badjatia N, Nogueira RG, Sims JR, Ogilvy CS, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:2891-2893
21. Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J, Stroes ES, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind placebo-controlled randomized trial. J Cereb Blood Flow Metab. 2009; 29:1444-1453
22. Jaschinski U, Scherer K, Lichtwarck M, Forst H. Impact of treatment with pravastatin on delayed ischemic disease and mortality after aneurysmal subarachnoid hemorrhage. Crit Care. 2008;12(Suppl 2):P112.
23. Macedo S, Bello Y, Silva A, Siqueira C, Siqueira S, Brito L. Effects of simvastatin in prevention of vasospasm in nontraumatic subarachnoid hemorrhage: preliminary data. Crit Care. 2009;13(Suppl 1):P103.
24. Kramer AH, Gurka MJ, Nathan B, Dumont AS, Kassell NF, Bleck TP. Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage. Neurosurgery. 2008;62: 422-427
25. Kerz T, Victor A, Beyer C, Trapp I, Heid F, Reisch R. A case control study of statin and magnesium administration in patients after aneurysmal subarachnoid hemorrhage: incidence of delayed cerebral ischemia and mortality. Neurol Res. 2008;30:893-897
26. Kern M, Lam MM, Knuckey NW, Lind CR. Statins may not protect against vasospasm in subarachnoid hemorrhage. J Clin Neurosci. 2009;16:527-530
27. McGirt MJ, Garces Ambrossi GL, Huang J, Tamargo RJ. Simvastatin for the prevention of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage; a ginle-institution prospective cohort study. J Neurosurg. 2009;110:968-974
28. Singhal AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology. 2005;64: 1008-1013
29. Mokowitz SI, Ahrens C, Provencio JJ, Chow M, Rasmussen PA. Prehemorrhage statin use and the risk of vasospasm after aneurysmal subarachnoid hemorrhage. Surg Neurol. 2009;71:311-318
30. Nolan CP, Macdonald RL. Can angiographic vasospasm be used as a surrogate marker in evaluating therapeutic interventions for cerebral vasospasm? Neurosurg Focus 2006;15(21):E1.
31. Haley EC Jr, Kassell NF, Torner JC. A randomized trial of nicardipine in subarachnoid hemorrhage: angiographic and transcranial Doppler ultrasound results. A report of the Cooperative Aneurysm Study. J Neurosurg. 1993;78:548-553
32. Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10:141-147
33. http://www.clinicaltrials.gov/ct2/show/NCT00731627?term= statins+and+subarachnoid+hemorrhage&rank=2, accessed August 27, 2009.
34. http://www.clinicaltrials.gov/ct2/show/NCT00795288?term= statins+and+subarachnoid+hemorrhage&rank=1, accessed August 27, 2009.
35. http://www.clinicaltrials.gov/ct2/show/NCT00487461?term= statins+and+subarachnoid+hemorrhage&rank=5,accessed August 27, 2009.